READY FOR RINVOQ?
Moderate UC, breakthrough symptoms on conventional therapy
Prior conventional therapy: 5-ASA, oral corticosteroids
- Diagnosed with left-sided colitis 5 years ago
- 5-ASA was originally working well when administered topically, but is now being administered orally
- Prescribed corticosteroids to manage flare-ups (has needed 3 courses in the past year)
- Bio-naïve*
- Wary of abdominal pain and unpredictable flares
- Often feels bowel urgency: elevated stool frequency (1–2 more than normal per day) with rectal bleeding <50% of the time
Clinical workup revealed moderate disease activity, confirmed by colonoscopy:
- Elevated fecal calprotectin (1512 mg/kg); colonoscopy showed marked erythema, friability, and erosions (adapted Mayo score† 6; endoscopic subscore 2)
- hs-CRP: 6.3 mg/L
*Without prior biologic failure and includes patients who had previous exposure to biologics but did not experience treatment failure. †The Adapted Mayo Score evaluates UC stage, based on 4 parameters: stool frequency, rectal bleeding, endoscopic evaluation, and Physician’s global assessment. Each parameter of the score ranges from 0 (normal or inactive disease) to 3 (severe activity). A score of 0–2 indicates remission, 3–5 mild activity, 6–10 moderate activity, and >10 severe activity.1,2
Note for affiliates: If these patient profile characteristics are used, the following references should be added and renumbered in sequential order within an affiliate's CLM: References: 1. Rutgeerts P, Sandborn WJ, Feagan BG, et al. N Engl J Med. 2005;353(23):2462-2476. doi:10.1056/NEJMoa050516 2. Schroeder KW, Tremaine WJ, Ilstrup DM. N Engl J Med. 1987;317(26):1625-1629. doi:10.1056/NEJM198712243172603